이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Shineco 관리

관리 기준 확인 3/4

Shineco's CEO는 Jennifer Zhan, Jul2021 에 임명되었습니다 의 임기는 2.92 년입니다. 총 연간 보상은 $ 70.00K, 85.7% 로 구성됩니다. 85.7% 급여 및 14.3% 보너스(회사 주식 및 옵션 포함). 는 $ 13.63K 가치에 해당하는 회사 주식의 0.067% 직접 소유합니다. 13.63K. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 2.9 년입니다.

주요 정보

Jennifer Zhan

최고 경영자

US$70.0k

총 보상

CEO 급여 비율	85.7%
CEO 임기	2.9yrs
CEO 소유권	0.07%
경영진 평균 재임 기간	2.3yrs
이사회 평균 재임 기간	2.9yrs

최근 관리 업데이트

Recent updates

Shineco CEO steps down, new CEO appointed

May 07

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

May 04

CEO 보상 분석

Jennifer Zhan 의 보수는 Shineco 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$14m
Dec 31 2023	n/a	n/a	-US$14m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	US$70k	US$60k	-US$10m
Mar 31 2023	n/a	n/a	US$2m
Dec 31 2022	n/a	n/a	US$2m
Sep 30 2022	n/a	n/a	US$2m
Jun 30 2022	US$70k	US$60k	-US$8m

보상 대 시장: Jennifer 의 총 보상 ($USD 70.00K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 683.56K ).

보상과 수익: Jennifer 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Jennifer Zhan (35 yo)

2.9yrs

테뉴어

US$70,000

보상

Ms. Jennifer Zhan has been Chief Executive Officer of Shineco, Inc. since July 15, 2021 and has been its Executive Director since July 14, 2021. She was a founding partner of Tian ‘Ang capital Beijing Inve...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jennifer Zhan	CEO & Executive Director	2.9yrs	US$70.00k	0.067% $ 14.6k
Sai Wang	CFO & Director	9.3yrs	US$106.00k	0.13% $ 28.2k
Xiqiao Liu	COO & Executive Director	2.3yrs	US$10.00k	0.067% $ 14.6k
Wang Xiaohui	Executive President	less than a year	데이터 없음	데이터 없음
Fenming Liu	Chief Scientist	no data	데이터 없음	데이터 없음
Qiyin Sun	Chief Medical Consultant	2.3yrs	데이터 없음	데이터 없음
Chi Keung Yan	Chief Strategy Officer	less than a year	데이터 없음	데이터 없음

2.3yrs

평균 재임 기간

44yo

평균 연령

경험이 풍부한 관리: SISI 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jennifer Zhan	CEO & Executive Director	2.9yrs	US$70.00k	0.067% $ 14.6k
Sai Wang	CFO & Director	8yrs	US$106.00k	0.13% $ 28.2k
Xiqiao Liu	COO & Executive Director	2.3yrs	US$10.00k	0.067% $ 14.6k
Aamir Quraishi	Independent Director	1.8yrs	US$10.00k	데이터 없음
Hu Li	Independent Director	2.8yrs	US$10.00k	데이터 없음
Jin Liu	Independent Director	3.8yrs	US$10.00k	데이터 없음
Mike Zhao	Independent Chairman of the Board	2.9yrs	US$10.00k	데이터 없음

2.9yrs

평균 재임 기간

49yo

평균 연령

경험이 풍부한 이사회: SISI 의 이사회는 경험(평균 재직 기간 2.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Shineco 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Shineco, Inc., Annual General Meeting, Feb 01, 2024

Shineco, Inc. Announces the Appointment of Two New Executive Officers

Shineco, Inc., Annual General Meeting, Jun 28, 2023

High number of new and inexperienced directors

Shineco, Inc. Appoints Aamir Ali Quraishi as Independent Director

Shineco, Inc. Resigns Yanzeng as Member of the Board of Directors

Recent updates

Shineco Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Requirement Under Nasdaq Listing Rule 5550(a)(2)

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Share price stability

New major risk - Financial position

Shineco, Inc., Annual General Meeting, Feb 01, 2024

Shineco, Inc. Announces the Appointment of Two New Executive Officers

New major risk - Share price stability

New major risk - Financial position

Full year 2023 earnings released: US$0.54 loss per share (vs US$2.60 loss in FY 2022)

Shineco Not Regains Compliance with the Nasdaq's Minimum Bid Price Requirement

Shineco, Inc.'S Subsidiary, Changzhou Biowin Pharmaceutical Co., Ltd., Receives Marketing Approval from China's Regulatory Body for Its Cardiac 5 Minute Test

New major risk - Market cap size

Shineco, Inc., Annual General Meeting, Jun 28, 2023

Third quarter 2023 earnings released: US$0.45 loss per share (vs US$0.30 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.15 loss per share (vs US$0.32 loss in 2Q 2022)

Shineco, Inc. (NasdaqCM:SISI) signed a letter of intent to acquire 80% stake in Dream Partner Limited for $40 million.

First quarter 2023 earnings released: US$0.17 loss per share (vs US$1.34 loss in 1Q 2022)

High number of new and inexperienced directors

Shineco Receives Deficiency Letter from Nasdaq

Full year 2022 earnings released: US$2.60 loss per share (vs US$4.73 loss in FY 2021)

Shineco, Inc. Appoints Aamir Ali Quraishi as Independent Director

Shineco, Inc. Resigns Yanzeng as Member of the Board of Directors

High number of new and inexperienced directors

Shineco, Inc. Announces Management Changes

Second quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Shineco, Inc. Appoints Qiyin Sun as Chief Medical Consultant

High number of new directors

Shineco, Inc. (NasdaqCM:SISI) entered into an agreement to acquire 51% stake in Xiang Peng You Kang (Beijing) Technology Co., Ltd.

Independent Director Harry Edelson has left the company

High number of new directors

Third quarter 2021 earnings released: US$2.36 loss per share (vs US$1.26 loss in 3Q 2020)

Shineco CEO steps down, new CEO appointed

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding terms of proposal to acquire a 51% stake in Mayah Biological Holdings Limited.

Shineco rallies on proposal to acquire 51% equity interests in Mayah Biological

Shineco, Inc. announced delayed 10-Q filing

New 90-day high: US$4.15

New 90-day high: US$3.82

New 90-day high: US$3.31

First quarter 2021 earnings released: US$0.35 loss per share

Full year earnings released - US$2.25 loss per share

New 90-day low - US$2.71

Shineco, Inc. Announces Management Changes

Shineco, Inc. (NasdaqCM:TYHT) signed a non-binding Letter of Intent to acquire 73.7% stake in Changzhou Biowin Pharmaceutical Co., Ltd from Beijing Kanghuayuan Technology Development Co., Ltd and Changzhou Kelinbo Venture Capital Partnership (limited partnership) for $25 million.

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령